IPO
IPO filing, visualized

Iambic Therapeutics, Inc.

IAM · Nasdaq424B4 · Oct 15, 2026Priced Oct 14, 2026

Priced Oct 14, 2026 · range was $15–$17 · latest SEC filing Nov 16, 2026.

Pinch-zoom for details.

The offering

Final price
$16.00
per share, from the final prospectus
Shares offered
9.38M
sold by the company
Raise at the final price
$150M
9,375,000 × $16, before fees

What the company does

Clinical-stage drug developer that uses AI and its own technology to discover medicines; no products approved for sale.

Revenue

Fiscal year

1st half

Operating result

Fiscal year

1st half

Net result

Fiscal year

1st half

Things to weigh

  • Loss-making: net loss of $50.1M in H1 2026.

The numbers

$FY2024FY2025YoYH1 2025H1 2026Change
Revenue1.19M9.43M+689%3.93M12.8M+225%
Operating result(53.9M)(82.3M)−52.8%(35.7M)(53.5M)−50.0%
Net result(47.9M)(77.3M)−61.4%(33.2M)(50.1M)−51.1%
$FY2024FY2025YoY
Revenue1.19M9.43M+689%
Operating result(53.9M)(82.3M)−52.8%
Net result(47.9M)(77.3M)−61.4%
$H1 2025H1 2026Change
Revenue3.93M12.8M+225%
Operating result(35.7M)(53.5M)−50.0%
Net result(33.2M)(50.1M)−51.1%

Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.

Risks

  1. We have a limited operating history and have incurred significant losses and negative cash flows, and we anticipate…
  2. We will require substantial additional capital, which may not be available on acceptable terms, if at all
  3. Our business depends on establishing and maintaining strategic partnerships, including with AbbVie, Takeda, Lundbeck…
  4. Our partners have significant discretion over whether and how to advance, prioritize and disclose partnered programs
  5. Our approach to drug discovery, which integrates AI with automated experimentation, is novel and unproven and may not lead to successful…
  6. Our drug candidates may cause undesirable side effects, and we may be unable to enroll patients…

The filing's own risk-factor headings, shortened.

Strategy

  1. Platform: Advance our platform, unlock additional capabilities, and expand our data moat
  2. Pipeline: Advance a differentiated, wholly owned preclinical and clinical pipeline
  3. Partnerships: Convert platform leadership into partnership revenue

The filing's own strategy headings, shortened.

Source: Iambic Therapeutics, Inc.'s Form 424B4, filed with the SEC on Oct 15, 2026 (final prospectus). Figures are as filed; changes are worked out from them. Not investment advice.

10KDecoder10KDecoder.com

10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.